Mechanisms, manifestations, and management of digoxin toxicity in the modern era.
Because of the common use of digoxin and because of its narrow therapeutic index, digoxin toxicity has been prevalent historically and, therefore, most clinicians are well aware of the classical dose/concentration-related signs and symptoms of toxicity. Yet, in the modern era the incidence of digoxin toxicity has been declining for a variety of reasons, including a new (lower) therapeutic range, the development of more effective drug therapies for heart failure, and more accurate dosing methods. In addition, digoxin toxicity, once commonly fatal, can now be quickly and effectively treated by the emergency administration of antidigoxin Fab fragments. Indeed, it may be possible to expand the use of Fab fragments to select patients with non-life-threatening digoxin toxicity, in order to save costs and improve patient comfort. Most cases of digoxin toxicity are caused by inappropriately high dosages, which are usually prescribed in the setting of renal dysfunction, while other cases can be attributed to system errors such as multiple prescriptions, poor patient counseling, or errors in transcribing. With modern computerized prescribing systems, such as direct physician order entry and prompts that alert the clinician to the potential for error, it is possible to decrease the incidence of digoxin toxicity even further. A realistic goal is to nearly eradicate once commonplace digoxin toxicity or at least make its occurrence a rare event.
Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois 60612, USA. jbauman@uic.edu
Jerry L
JL
Bauman
Robert J
RJ
Didomenico
William L
WL
Galanter
D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data / Q000639:trends; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004077:Digoxin / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006331:Heart Diseases / Q000188:drug therapy*; D006801:Humans
D002316:Cardiotonic Agents; D004077:Digoxin